GLPwatch
Papers (9189)
Page 124 of 154, ranked by citation count.
- Liraglutide innovations: a comprehensive review of patents (2014-2024).
- A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
- Exendin-4 blockade of T1R2/T1R3 activation improves Pseudomonas aeruginosa-related pneumonia in an animal model of chemically induced diabetes.
- Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.
- Glucagon-like peptide-1 receptor PET/CT with <sup>68</sup>Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.
- Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.
- Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.
- Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening.
- Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
- Dissecting Hidden Liraglutide Oligomerization Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics.
- Editorial commentary: Weight loss for cardiovascular disease prevention - is semaglutide the answer?
- Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson's disease when considering the coexisting effects of diabetes mellitus.
- Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study.
- Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
- Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
- Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
- Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
- Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.
- Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
- [Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes].
- Semaglutide in NASH-related cirrhosis: still a long way to go?
- [Modern strategies for the treatment of childhood obesity].
- From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.
- Gateways to clinical trials.
- Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial.
- Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.
- Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia.
- SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
- Accuracy of dosage volume for halfway doses in the Victoza Pen.
- Clinical trials for adolescent obesity: cooking up an alphabet stew of what to do.
- [Effect of adipose-derived mesenchymal stem cells and liraglutide on acute lung injury].
- Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
- Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.
- Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.
- Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
- Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.
- Drugs and devices for weight management.
- Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system.
- [The protective effect of exenatide on the renal injury in diabetic rats].
- Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
- Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.
- A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
- Liraglutide and systolic blood pressure.
- Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.
- Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress.
- Obesity in China: current progress and future prospects.
- Evaluating the Efficacy of ChatGPT vs. Google Gemini in Generating Patient Education Materials for GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Tirzepatide): A Cross-Sectional Study.
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.
- The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.
- Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers.
- One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients.
- Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
- Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.
- SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes.
- Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials-A Short Review.
- Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
- Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?
- A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.